Back to top
more

Incyte (INCY)

(Delayed Data from NSDQ)

$75.59 USD

75.59
1,583,946

+0.70 (0.93%)

Updated Aug 1, 2025 04:00 PM ET

After-Market: $75.60 +0.01 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

5 Toxic Stocks to Dump or Play Short Now

by Zacks Equity Research

Higher price of the toxic stocks can be attributed to either an irrational exuberance associated with them or some serious fundamental lacuna.

    Zacks Equity Research

    Lilly-Incyte Rheumatoid Arthritis Drug PDUFA Date Extended

    by Zacks Equity Research

    Eli Lilly and Company (LLY) and Incyte Corporation (INCY) announced that the FDA has extended the time to review the company's NDA for baricitinib for the treatment of rheumatoid arthritis (RA).

      Arpita Dutt headshot

      4 Stocks in Focus as Biotech M&A Hopes Surge on Takeda-ARIAD Deal

      by Arpita Dutt

      Takeda to Buy ARIAD, More M&As to Follow in Biotech Sector?

        Zacks Equity Research

        Incyte/Merck to Start More Epacadostat-Keytruda Studies

        by Zacks Equity Research

        Incyte (INCY) and Merck (MRK) announced that they have decided to initiate additional pivotal studies on epacadostat, in combination with Merck's Keytruda.

          Zacks Equity Research

          Bluerock Residential Growth REIT, Cal-Maine Foods, Incyte, Eli Lilly and Synergy Pharmaceuticals highlighted as Zacks Bull and Bear of the Day

          by Zacks Equity Research

          Bluerock Residential Growth REIT, Cal-Maine Foods, Incyte, Eli Lilly and Synergy Pharmaceuticals highlighted as Zacks Bull and Bear of the Day

            Zacks Equity Research

            Incyte Treats First Patient in Phase II GVHD Study on Jakafi

            by Zacks Equity Research

            Incyte Corporation (INCY) announced that the first patient has been treated in the pivotal phase II REACH-1 study assessing its marketed drug Jakafi, in combination with corticosteroids, for the treatment of GVHD.

              Arpita Dutt headshot

              Two Key FDA Decisions to Watch Out for in January 2017

              by Arpita Dutt

              Incyte (INCY) and Synergy (SGYP) have important regulatory events coming up this month.

                Zacks Equity Research

                The Zacks Analyst Blog Highlights: Alexion Pharmaceuticals, Celgene, Incyte, Eli Lilly, Regeneron Pharmaceuticals and Ophthotech

                by Zacks Equity Research

                The Zacks Analyst Blog Highlights: Alexion Pharmaceuticals, Celgene, Incyte, Eli Lilly, Regeneron Pharmaceuticals and Ophthotech

                  Zacks Equity Research

                  Incyte/Merus Ink Collaboration for Bispecific Antibodies

                  by Zacks Equity Research

                  Incyte (INCY) entered into an agreement with Merus (MRUS) to discover and develop bispecific antibodies using the latter's proprietary Biclonics technology platform.

                    Zacks Equity Research

                    Incyte/Lilly Olumiant Wins CHMP Nod for Rheumatoid Arthritis

                    by Zacks Equity Research

                    Incyte (INCY) and Eli Lilly (LLY) announced that the EMA's CHMP has issued a positive opinion for the approval of Olumiant (baricitinib).

                      Zacks Equity Research

                      Incyte Jakafi Positive in Pooled Analysis of Five-Year Data

                      by Zacks Equity Research

                      Incyte (INCY) announced pooled analysis of five-year data from two phase III studies on Jakafi, which support previous long-term results.

                        Zacks Equity Research

                        Agenus' INCAGN1876 in Phase I/II Study for Solid Tumors

                        by Zacks Equity Research

                        Agenus (AGEN) announced that it has dosed the first patient in a phase I/II study on INCAGN1949 for the treatment of patients with solid tumors.

                          Indradip Ghosh headshot

                          New Strong Buy Stocks for October 11th

                          by Indradip Ghosh

                          Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Tuesday

                            Zacks Equity Research

                            New Strong Buy Stocks for August 10th

                            by Zacks Equity Research

                            Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Wednesday

                              Kevin Matras headshot

                              A Company's First Profit Can Mean Big Profits to Investors

                              by Kevin Matras

                              Kevin Matras screens for companies showing their 'first' profit, and explains why they are ones to watch. Highlighted stocks include OPHT, XNPT, OSUR, INCY and AGIO.